Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literatureORTEGA, Jose; HAYES, J. Michael; ANTONIA, Scott et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 1, pp 187-190, issn 0344-5704, 4 p.Article

Gene therapy for lung cancerHAURA, Eric B; SOTOMAYOR, Eduardo; ANTONIA, Scott J et al.Molecular biotechnology. 2003, Vol 25, Num 2, pp 139-148, issn 1073-6085, 10 p.Article

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. CommentaryJOCHAM, Dieter; RICHTER, Axel; DOEHN, Christian et al.Lancet (British edition). 2004, Vol 363, Num 9409, pp 583-584, issn 0140-6736, 8 p.Article

Randomized International Phase III Trial of ERCC1 and RRM1 Expression―Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non―Small-Cell Lung CancerBEPLER, Gerold; WILLIAMS, Charles; CHIAPPORI, Alberto et al.Journal of clinical oncology. 2013, Vol 31, Num 19, pp 2404-2412, issn 0732-183X, 9 p.Article

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaTARIQ MAHMOOD, S; AGRESTA, Samuel; ANTONIA, Scott et al.International journal of cancer (Print). 2011, Vol 129, Num 8, pp 1963-1969, issn 0020-7136, 7 p.Article

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung CancerHAURA, Eric B; TANVETYANON, Tawee; LANXI SONG et al.Journal of clinical oncology. 2010, Vol 28, Num 8, pp 1387-1394, issn 0732-183X, 8 p.Article

Phase I/II Trial of Tremelimumab in Patients With Metastatic MelanomaCAMACHO, Luis H; ANTONIA, Scott; RIBAS, Antoni et al.Journal of clinical oncology. 2009, Vol 27, Num 7, pp 1075-1081, issn 0732-183X, 7 p.Article

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung CancerCHIAPPORI, Alberto A; HAURA, Eric; SIMON, George et al.Clinical cancer research. 2008, Vol 14, Num 5, pp 1464-1469, issn 1078-0432, 6 p.Article

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinTOLCHER, Anthony W; MITA, Alain; KEATING, Anne et al.Journal of clinical oncology. 2008, Vol 26, Num 32, pp 5198-5203, issn 0732-183X, 6 p.Article

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsMIRZA, Noweeda; FISHMAN, Mayer; FRICKE, Ingo et al.Cancer research (Baltimore). 2006, Vol 66, Num 18, pp 9299-9307, issn 0008-5472, 9 p.Article

Phase 2 Trial of Docetaxel and Gefitinib in the First-Line Treatment of Patients With Advanced Nonsmall-Cell Lung Cancer (NSCLC) Who Are 70 Years of Age or OlderSIMON, George R; EXTERMANN, Martine; BEPLER, Gerold et al.Cancer. 2008, Vol 112, Num 9, pp 2021-2029, issn 0008-543X, 9 p.Article

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancerANTONIA, Scott J; MIRZA, Noweeda; MENANDER, Kerstin et al.Clinical cancer research. 2006, Vol 12, Num 3, pp 878-887, issn 1078-0432, 10 p., 1Article

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanomaLEE, Jeffrey R; DALTON, Rory R; MESSINA, Jane L et al.Laboratory investigation. 2003, Vol 83, Num 10, pp 1457-1466, issn 0023-6837, 10 p.Article

Phase I trial of A B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinomaANTONIA, Scott J; SEIGNE, John; CANTOR, Alan et al.The Journal of urology. 2002, Vol 167, Num 5, pp 1995-2000, issn 0022-5347Article

A GM-CSF/CD40L producing cell augments anti-tumor T cell responsesDESSUREAULT, Sophie; ALSARRAJ, Marwan; MCCARTHY, Susan et al.The Journal of surgical research. 2005, Vol 125, Num 2, pp 173-181, issn 0022-4804, 9 p.Article

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejectionFRIBERG, Maria; JENNINGS, Ronald; ALSARRAJ, Marwan et al.International journal of cancer. 2002, Vol 101, Num 2, pp 151-155, issn 0020-7136, 5 p.Article

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenaseMUNN, David H; SHARMA, Madhav D; SLINGLUFF, Craig L et al.Science (Washington, D.C.). 2002, Vol 297, Num 5588, pp 1867-1870, issn 0036-8075Article

COMBINATION OF EXTERNAL BEAM RADIOTHERAPY (EBRT) WITH INTRATUMORAL INJECTION OF DENDRITIC CELLS AS NEO-ADJUVANT TREATMENT OF HIGH-RISK SOFT TISSUE SARCOMA PATIENTSFINKELSTEIN, Steven E; ICLOZAN, Cristina; BERMAN, Claudia et al.International journal of radiation oncology, biology, physics. 2012, Vol 82, Num 2, pp 924-932, issn 0360-3016, 9 p.Article